ReviewMayo Clinic proceedings2011
Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci.
Review in Mayo Clinic proceedings, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 149 citations in OpenAlex.
- Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE.Annals of clinical microbiology and antimicrobials · 2016Trial
- Virulence traits and bacterial interactions within the complex microbial population in urinary double-J catheters.Frontiers in microbiology · 2025Article
- Unveiling the uncommon: vault hematoma and vault cellulitis following hysterectomy - a comprehensive narrative review.Przeglad menopauzalny = Menopause review · 2024Review
- Novel drug candidates against antibiotic-resistant microorganisms: A review.Iranian journal of basic medical sciences · 2024Review
- Molecular characterization of invasiveMicrobiology spectrum · 2023Article
- Evaluation of the Antibacterial and Antibiofilm Effects of Ethyl Acetate Root Extracts fromTheScientificWorldJournal · 2023Article
- Library Screening for Synergistic Combinations of FDA-Approved Drugs and Metabolites with Vancomycin against VanA-Type Vancomycin-Resistant Enterococcus faecium.Microbiology spectrum · 2022Article
- Effect of Vancomycin on Cytoplasmic Peptidoglycan Intermediates andJournal of bacteriology · 2021Article
- Symptomatic pelvic hematoma following hysterectomy: risk factors, bacterial pathogens and clinical outcome.BMC women's health · 2020Article
- Vancomycin intermediate resistantAfrican health sciences · 2020Article
- Pharmacogenomics of Antibiotics.International journal of molecular sciences · 2020Review
- Structure of a proton-dependent lipid transporter involved in lipoteichoic acids biosynthesis.Nature structural & molecular biology · 2020Article
- Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in anAntimicrobial agents and chemotherapy · 2020Article
- Assessment of Susceptibility to Five Common Antibiotics and Their Resistance Pattern in Clinical Enterococcus Isolates.Iranian journal of pathology · 2020Article
- Steady-state Pharmacokinetics of Vancomycin in Children Admitted to Pediatric Intensive Care Unit of a Tertiary Referral Center.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2019Article
- Trends in Antimicrobial Drug Resistance ofAntibiotics (Basel, Switzerland) · 2019Article
- Comparative In Vitro Activities of New Antibiotics for the Treatment of Skin Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Daptomycin Resistance and Tolerance Due to Loss of Function in Staphylococcus aureusAntimicrobial agents and chemotherapy · 2019Article
- Functional insights into the Streptococcus pneumoniae HicBA toxin-antitoxin system based on a structural study.Nucleic acids research · 2018Article
- A Phage Lysin Fused to a Cell-Penetrating Peptide Kills Intracellular Methicillin-Resistant Staphylococcus aureus in Keratinocytes and Has Potential as a Treatment for Skin Infections in Mice.Applied and environmental microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Gram-positive bacteria cause a broad spectrum of disease in immunocompetent and immunocompromised hosts. Despite increasing knowledge about resistance transmission patterns and new antibiotics, these organisms continue to cause significant morbidity and mortality, especially in the health care setting. Methicillin-resistant Staphylococcus aureus poses major problems worldwide as a cause of nosocomial infection and has emerged as a cause of community-acquired infections. This change in epidemiology affects choices of empirical antibiotics for skin and skin-structure infections and community-acquired pneumonia in many settings. Throughout the world, the treatment of community-acquired pneumonia and other respiratory tract infections caused by penicillin-resistant Streptococcus pneumoniae has been complicated by resistance to β-lactam and macrolide antibacterial drugs. Vancomycin-resistant enterococci are a major cause of infection in the hospital setting and remain resistant to treatment with most standard antibiotics. Treatment of diseases caused by resistant gram-positive bacteria requires appropriate use of available antibiotics and stewardship to prolong their effectiveness. In addition, appropriate and aggressive infection control efforts are vital to help prevent the spread of resistant pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.